https://doi.org/10.17037/DATA.00000781
An anonymised dataset of 199 pediatric patients aged 3-18 years of age, enrolled in the prospective Muhimbili Sickle Cohort (MSC), (Makani et al. PloS ONE 2011), whose parent or guardian consented to participate, which included having blood and DNA samples archived for studies relating to understanding the pathophysiology of sickle cell disease in Tanzanian patients. The dataset contains variables on age, sex, sickle phenotype (derived from electrophoresis and high performance liquid chromatography), history of previous blood transfusion and averaged steady state hemoglobin concentrations over the previous year prior to the samples included in this analysis. Samples included in this analysis were collected at scheduled routine clinic visits at which children were assessed by the attending physician as “clinically well” with no current pain, no fever and were malaria test (smear and or rapid test) negative, and had no reported or recorded hospitalization in the previous month. Laboratory data from the analysed samples include complete blood count data, clinical chemistry values, inflammatory markers, iron markers, erythropoietin and hepcidin. Alpha thalassaemia 3.7 deletion and glucose-6-phosphate dehydrogenase deficiency as potentially disease modifying genotypes are also included.
Please see details in associated manuscript: Lee et al. Decreased hepcidin levels are associated with low steady-state hemoglobin in children with sickle cell disease in Tanzania. EBioMed 2018.
Dar es Salaam, Tanzania
Samples were collected between 2006 – 2009 and the final analysis dataset with all laboratory values included was completed in 2015.
The study received ethical approval from Muhimbili University of Health and Allied Sciences reference MU/RP/AEC/VOL XI/33) and the London School of Hygiene & Tropical Medicine (reference 5158).
Sickle cell disease, iron metabolism, hepcidin, children
English
Decreased hepcidin levels are associated with low steady-state hemoglobin in children with sickle cell disease in Tanzania
The Wellcome Trust, the UK Medical Research Council and the Bill and Melinda Gates Foundation.
The Wellcome Trust (094780, 080025, 095009 & 070114), MRC UK (MC-A760-5QX00), NIHR Oxford Biomedical Research Centre, and the Bill and Melinda Gates Foundation ("Hepcidin and Iron in Global Health", OPP1055865).
Forename | Surname | Faculty / Dept | Institution | Role |
Sharon | Cox | Epidemiology and Population Health / Population Health | London School of Hygiene & Tropical Medicine | Data Creator |
Julie | Makani | Muhimbili University of Health & Allied Sciences | Data Creator | |
Nathan | Lee | Data Creator | ||
Raphael | Sangeda | Data Creator |
Filename | Description | Access status | Licence |
Hepcidin_dataset | Hepcidin dataset - CSV and Excel format | Request access for all | Data sharing agreement |
Codebook.html | Dataset codebook for manuscript Lee et al EBioMed 2018 | Open to all | CC-BY |
scd_information_sheet.pdf | Consent form and informed sheet | Open to all | CC-BY |